应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SXTP 60 degrees pharmaceuticals, Inc.
盘前交易 07-31 05:47:37 EDT
1.25
-0.24
-16.11%
盘前
1.10
-0.15
-12.00%
05:44 EDT
最高
1.68
最低
1.05
成交量
56.33万
今开
1.51
昨收
1.49
日振幅
42.28%
总市值
332.41万
流通市值
311.28万
总股本
265.93万
成交额
77.08万
换手率
22.62%
流通股本
249.02万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
60 Degrees Pharmaceuticals 将就他非诺喹治疗巴贝斯虫病的新药申请路径,请求与FDA召开会议
美股速递 · 07-30 05:00
60 Degrees Pharmaceuticals 将就他非诺喹治疗巴贝斯虫病的新药申请路径,请求与FDA召开会议
60 Degrees Pharmaceuticals宣布住院巴贝斯虫病研究达到最低入组人数;中期数据解读计划于2026年10月6日前公布
美股速递 · 07-30 04:05
60 Degrees Pharmaceuticals宣布住院巴贝斯虫病研究达到最低入组人数;中期数据解读计划于2026年10月6日前公布
60 Degrees Pharmaceuticals与佛罗里达州立大学达成独家期权协议,共同推进栗精胺用于蜱传疾病治疗
美股速递 · 07-08
60 Degrees Pharmaceuticals与佛罗里达州立大学达成独家期权协议,共同推进栗精胺用于蜱传疾病治疗
60 Degrees Pharmaceuticals宣布数据安全监测委员会对Tafenoquine治疗伴有重度疲劳的慢性巴贝斯虫病患者的B-free二期研究给予积极推荐
美股速递 · 07-01
60 Degrees Pharmaceuticals宣布数据安全监测委员会对Tafenoquine治疗伴有重度疲劳的慢性巴贝斯虫病患者的B-free二期研究给予积极推荐
60 Degrees Pharmaceuticals与佛罗里达州立大学签署独家专利许可协议,将澳大利亚栗子提取物作为植物补充剂非处方使用
美股速递 · 06-11
60 Degrees Pharmaceuticals与佛罗里达州立大学签署独家专利许可协议,将澳大利亚栗子提取物作为植物补充剂非处方使用
60 Degrees Pharmaceuticals:有望在2028年第一季度末前向FDA提交他非诺喹新药申请
美股速递 · 06-04
60 Degrees Pharmaceuticals:有望在2028年第一季度末前向FDA提交他非诺喹新药申请
60 Degrees Pharmaceuticals 宣布首个季节性患者提前入组他非诺喹治疗住院巴贝斯虫病的临床试验
美股速递 · 05-26
60 Degrees Pharmaceuticals 宣布首个季节性患者提前入组他非诺喹治疗住院巴贝斯虫病的临床试验
60 Degrees Pharmaceuticals宣布疟疾预防药物Arakoda登陆Runway Health平台
美股速递 · 04-15
60 Degrees Pharmaceuticals宣布疟疾预防药物Arakoda登陆Runway Health平台
60 Degrees Pharmaceuticals向FDA提交澳大利亚栗子提取物新膳食成分申请
美股速递 · 03-18
60 Degrees Pharmaceuticals向FDA提交澳大利亚栗子提取物新膳食成分申请
60 Degrees Pharmaceuticals, Inc.股价飙升18.35% 市值涨52.55万美元
市场透视 · 03-11
60 Degrees Pharmaceuticals, Inc.股价飙升18.35% 市值涨52.55万美元
60度制药宣布扩大使用临床试验中所有患者经他非诺喹治疗后巴贝斯虫病痊愈
美股速递 · 03-11
60度制药宣布扩大使用临床试验中所有患者经他非诺喹治疗后巴贝斯虫病痊愈
60 Degrees Pharmaceuticals, Inc.盘中异动 下午盘股价大跌6.77%
市场透视 · 03-10
60 Degrees Pharmaceuticals, Inc.盘中异动 下午盘股价大跌6.77%
60 Degrees Pharmaceuticals, Inc.盘中异动 大幅下挫5.56%
市场透视 · 02-21
60 Degrees Pharmaceuticals, Inc.盘中异动 大幅下挫5.56%
60 Degrees Pharmaceuticals Inc重获纳斯达克最低股价合规资格——SEC文件披露
美股速递 · 02-12
60 Degrees Pharmaceuticals Inc重获纳斯达克最低股价合规资格——SEC文件披露
60 Degrees Pharmaceuticals, Inc.盘中异动 早盘股价大跌7.06%报3.82美元
市场透视 · 02-10
60 Degrees Pharmaceuticals, Inc.盘中异动 早盘股价大跌7.06%报3.82美元
60 Degrees Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.18%
市场透视 · 02-05
60 Degrees Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.18%
60 Degrees Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.13%
市场透视 · 2025-03-10
60 Degrees Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.13%
60 Degrees Pharmaceuticals, Inc.盘中异动 大幅跳水6.06%
市场透视 · 2025-03-04
60 Degrees Pharmaceuticals, Inc.盘中异动 大幅跳水6.06%
60 Degrees Pharmaceuticals, Inc.盘中异动 大幅跳水5.38%报1.90美元
市场透视 · 2025-02-27
60 Degrees Pharmaceuticals, Inc.盘中异动 大幅跳水5.38%报1.90美元
60 Degrees Pharmaceuticals, Inc.盘中异动 大幅拉升6.77%报2.05美元
市场透视 · 2025-02-26
60 Degrees Pharmaceuticals, Inc.盘中异动 大幅拉升6.77%报2.05美元
暂无数据
公司概况
公司名称:
60 degrees pharmaceuticals, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
60 Degrees Pharmaceuticals, Inc.于2022年6月1日在特拉华州注册成立,此前与一家同名的有限责任公司合并。该公司是一家专业制药公司,专注于开发和商业化治疗传染病的疗法。其产品Arakoda(一种疟疾预防药物)自2019年起上市,其研发管线还包括其他虫媒、真菌和病毒性疾病项目。
发行价格:
--
{"stockData":{"symbol":"SXTP","market":"US","secType":"STK","nameCN":"60 degrees pharmaceuticals, Inc.","latestPrice":1.25,"timestamp":1785441600000,"preClose":1.49,"halted":0,"volume":563315,"hourTrading":{"tag":"盘前","latestPrice":1.1,"preClose":1.25,"latestTime":"05:44 EDT","volume":3334,"amount":4031.5798213999997,"timestamp":1785491094167,"change":-0.15,"changeRate":-0.12,"amplitude":0.104},"delay":0,"changeRate":-0.1610738255033557,"floatShares":2490200,"shares":2659288,"eps":-10.4652,"marketStatus":"盘前交易","change":-0.24,"latestTime":"07-31 05:47:37 EDT","open":1.51,"high":1.68,"low":1.05,"amount":770839.9080109999,"amplitude":0.422819,"askPrice":1.22,"askSize":918,"bidPrice":0.9237,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-10.4652,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785504600000},"marketStatusCode":1,"adr":0,"listingDate":1686801600000,"exchange":"NASDAQ","adjPreClose":1.25,"preHourTrading":{"tag":"盘前","latestPrice":1.1,"preClose":1.25,"latestTime":"05:44 EDT","volume":3334,"amount":4031.5798213999997,"timestamp":1785491094167,"change":-0.15,"changeRate":-0.12,"amplitude":0.104},"postHourTrading":{"tag":"盘后","latestPrice":1.2,"preClose":1.25,"latestTime":"19:58 EDT","volume":51610,"amount":63681.4731,"timestamp":1785455933226,"change":-0.05,"changeRate":-0.04,"amplitude":0.06248},"volumeRatio":3.788524839256285},"requestUrl":"/m/hq/s/SXTP/tweets","defaultTab":"tweets","newsList":[{"id":"1149797615","title":"60 Degrees Pharmaceuticals 将就他非诺喹治疗巴贝斯虫病的新药申请路径,请求与FDA召开会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1149797615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149797615?lang=zh_cn&edition=full","pubTime":"2026-07-30 05:00","pubTimestamp":1785358841,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals 公司计划就他非诺喹(Tafenoquine)用于治疗巴贝斯虫病(Babesiosis)的新药申请(NDA)路径,正式请求与美国食品药品监督管理局(FDA)举行会议。这一举措标志着该公司在推进该候选药物的监管进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180936305","title":"60 Degrees Pharmaceuticals宣布住院巴贝斯虫病研究达到最低入组人数;中期数据解读计划于2026年10月6日前公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1180936305","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180936305?lang=zh_cn&edition=full","pubTime":"2026-07-30 04:05","pubTimestamp":1785355520,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals, Inc. 今日对外公布,其针对住院巴贝斯虫病患者的临床研究已成功达成最低入组人数这一关键里程碑。这一进展标志着该项目的推进迈出了坚实一步。\n公司同时明确,计划在2026年10月6日之前,对外发布该研究的中期数据解读。这一时间表的设定,为市场及医学界提供了清晰的预期。巴贝斯虫病作为一种罕见且可能危及生命的寄生虫感染,目前有效的治疗选择十分有限,因此这项研究的每一步进展都备受关注。\n围绕此项研究的后续动态,尤其是即将公布的中期数据,投资者和行业观察者都将予以密切关注。这些数据或将为评估相关治疗方案的潜力提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SXTPW","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172283578","title":"60 Degrees Pharmaceuticals与佛罗里达州立大学达成独家期权协议,共同推进栗精胺用于蜱传疾病治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1172283578","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172283578?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:03","pubTimestamp":1783512208,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals 宣布,已与佛罗里达州立大学签署一项独家期权协议,旨在共同推进化合物栗精胺(Castanospermine)用于治疗蜱传疾病的研发工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115356434","title":"60 Degrees Pharmaceuticals宣布数据安全监测委员会对Tafenoquine治疗伴有重度疲劳的慢性巴贝斯虫病患者的B-free二期研究给予积极推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=1115356434","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115356434?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:06","pubTimestamp":1782907607,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals宣布,其数据安全监测委员会已对使用Tafenoquine治疗伴有重度疲劳的慢性巴贝斯虫病患者的B-free二期研究给出了积极的推荐意见。这一进展标志着该药物在应对这一特定患者群体需求的研究道路上迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159924907","title":"60 Degrees Pharmaceuticals与佛罗里达州立大学签署独家专利许可协议,将澳大利亚栗子提取物作为植物补充剂非处方使用","url":"https://stock-news.laohu8.com/highlight/detail?id=1159924907","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159924907?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:05","pubTimestamp":1781179544,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals已与佛罗里达州立大学达成一项独家专利许可协议,旨在将澳大利亚栗子提取物作为植物补充剂进行非处方用途的开发与商业化。该协议标志着公司在其产品管线拓展方面迈出了重要一步,为其在植物补充剂领域的布局提供了关键的技术和知识产权支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183362639","title":"60 Degrees Pharmaceuticals:有望在2028年第一季度末前向FDA提交他非诺喹新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1183362639","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183362639?lang=zh_cn&edition=full","pubTime":"2026-06-04 04:59","pubTimestamp":1780520371,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件,生物制药公司60 Degrees Pharmaceuticals, Inc.可能将在2028年第一季度结束前,向美国食品药品监督管理局提交其药物他非诺喹的新药申请。\n这份监管文件披露了公司关于该候选药物的最新进展时间表。他非诺喹是一种正在研发中的药物,其目标适应症尚未在文件中具体说明。\n若申请按计划提交,将标志着该药物研发过程中的一个重要监管里程碑。新药申请的提交是药物获准在美国市场上市销售的关键步骤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164428215","title":"60 Degrees Pharmaceuticals 宣布首个季节性患者提前入组他非诺喹治疗住院巴贝斯虫病的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1164428215","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164428215?lang=zh_cn&edition=full","pubTime":"2026-05-26 20:02","pubTimestamp":1779796938,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals 宣布,其用于治疗住院巴贝斯虫病患者的他非诺喹临床试验,已提前完成首位季节性患者的入组工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190705999","title":"60 Degrees Pharmaceuticals宣布疟疾预防药物Arakoda登陆Runway Health平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1190705999","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190705999?lang=zh_cn&edition=full","pubTime":"2026-04-15 20:05","pubTimestamp":1776254720,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals Inc. 近日宣布,其疟疾预防药物Arakoda已正式在Runway Health官方网站上线销售。Arakoda作为公司核心抗疟产品,此次渠道拓展标志着企业数字营销战略的重要突破。通过Runway Health的远程医疗服务,用户可完成在线问诊并获取处方,简化了传统购药流程。公司表示,这一举措契合后疫情时代数字医疗发展趋势,未来将继续探索与其他线上医疗平台的合作可能。目前Arakoda已在Runway Health平台开启预售,首批订单将于下周开始配送。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139308427","title":"60 Degrees Pharmaceuticals向FDA提交澳大利亚栗子提取物新膳食成分申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1139308427","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139308427?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:02","pubTimestamp":1773835353,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals, Inc.已向美国食品药品监督管理局提交新膳食成分申请,涉及澳大利亚栗子提取物。该申请标志着公司正式启动该成分在美国膳食补充剂市场的合规准入流程。根据FDA规定,新膳食成分需通过NDIN程序进行安全性评估后方可上市。此次提交的澳大利亚栗子提取物若获批准,将可用于膳食补充剂产品。植物提取物作为膳食补充剂核心原料,其市场规模近年来稳步扩大。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618040904","title":"60 Degrees Pharmaceuticals, Inc.股价飙升18.35% 市值涨52.55万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618040904","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618040904?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:31","pubTimestamp":1773235872,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日21时31分,60 Degrees Pharmaceuticals, Inc.股票出现波动,股价快速上涨18.35%。60 Degrees Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.08%。60 Degrees Pharmaceuticals, Inc.公司简介:60 Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311213113a6b848f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311213113a6b848f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166654655","title":"60度制药宣布扩大使用临床试验中所有患者经他非诺喹治疗后巴贝斯虫病痊愈","url":"https://stock-news.laohu8.com/highlight/detail?id=1166654655","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166654655?lang=zh_cn&edition=full","pubTime":"2026-03-11 19:24","pubTimestamp":1773228251,"startTime":"0","endTime":"0","summary":"在近期开展的扩大使用临床试验中,60度制药公司宣布,所有接受他非诺喹治疗的巴贝斯虫病患者均已实现临床痊愈。这一突破性进展为罕见寄生虫病的治疗提供了新的可能性,也标志着该创新疗法的有效性得到进一步验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618938230","title":"60 Degrees Pharmaceuticals, Inc.盘中异动 下午盘股价大跌6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618938230","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618938230?lang=zh_cn&edition=full","pubTime":"2026-03-10 02:24","pubTimestamp":1773080640,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日02时24分,60 Degrees Pharmaceuticals, Inc.股票出现波动,股价大幅下挫6.77%。60 Degrees Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.50%。60 Degrees Pharmaceuticals, Inc.公司简介:60 Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031002240097ab4e70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031002240097ab4e70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613245840","title":"60 Degrees Pharmaceuticals, Inc.盘中异动 大幅下挫5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613245840","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613245840?lang=zh_cn&edition=full","pubTime":"2026-02-21 05:00","pubTimestamp":1771621216,"startTime":"0","endTime":"0","summary":"北京时间2026年02月21日05时00分,60 Degrees Pharmaceuticals, Inc.股票出现异动,股价急速下跌5.56%。60 Degrees Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.08%。60 Degrees Pharmaceuticals, Inc.公司简介:60 Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221050016a4b764dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221050016a4b764dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199905465","title":"60 Degrees Pharmaceuticals Inc重获纳斯达克最低股价合规资格——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1199905465","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199905465?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:06","pubTimestamp":1770905188,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新文件披露,60 Degrees Pharmaceuticals Inc已成功重新符合纳斯达克市场的最低股价要求。该公司此前因股价连续低于1美元面临退市风险,此次合规状态的恢复标志着其股价已稳定回升至纳斯达克规定的门槛之上。\n这一进展消除了市场对该公司上市地位稳定性的担忧,也为投资者注入了信心。作为一家专注于热带疾病治疗研发的生物制药企业,60 Degrees Pharmaceuticals Inc此番合规状况的改善,可能为其后续融资及业务拓展创造更有利的条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610621530","title":"60 Degrees Pharmaceuticals, Inc.盘中异动 早盘股价大跌7.06%报3.82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610621530","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610621530?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:34","pubTimestamp":1770734086,"startTime":"0","endTime":"0","summary":"北京时间2026年02月10日22时34分,60 Degrees Pharmaceuticals, Inc.股票出现异动,股价急速跳水7.06%。60 Degrees Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.03%。其相关个股中,Quince Therapeutics, Inc.、Evommune, Inc.、Abpro Holdings, Inc涨幅较大,Abpro Holdings, Inc、Phio Pharmaceuticals Corp.、Quince Therapeutics, Inc.较为活跃,换手率分别为1013.88%、641.02%、479.08%,振幅较大的相关个股有Quince Therapeutics, Inc.、Abpro Holdings, Inc、Evommune, Inc.,振幅分别为52.69%、15.79%、12.95%。60 Degrees Pharmaceuticals, Inc.公司简介:60 Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210223446a494088f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210223446a494088f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609264123","title":"60 Degrees Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609264123","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609264123?lang=zh_cn&edition=full","pubTime":"2026-02-05 00:21","pubTimestamp":1770222068,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日00时21分,60 Degrees Pharmaceuticals, Inc.股票出现波动,股价急速下跌5.18%。60 Degrees Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.36%。60 Degrees Pharmaceuticals, Inc.公司简介:60 Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020500210997a4e4e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020500210997a4e4e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518627595","title":"60 Degrees Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518627595","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518627595?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:41","pubTimestamp":1741617699,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时41分,60 Degrees Pharmaceuticals, Inc.股票出现波动,股价快速下挫5.13%。60 Degrees Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.08%。其相关个股中,Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大,Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃,换手率分别为3485.77%、753.31%、636.86%,振幅较大的相关个股有Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.,振幅分别为41.36%、40.33%、40.24%。60 Degrees Pharmaceuticals, Inc.公司简介:60 Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022414096404721&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022414096404721&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516665908","title":"60 Degrees Pharmaceuticals, Inc.盘中异动 大幅跳水6.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516665908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516665908?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:57","pubTimestamp":1741035437,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时57分,60 Degrees Pharmaceuticals, Inc.股票出现波动,股价大幅跳水6.06%。60 Degrees Pharmaceuticals, Inc.股票所在的生物技术行业中,整体跌幅为0.12%。60 Degrees Pharmaceuticals, Inc.公司简介:60 Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304045717989a64b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304045717989a64b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514382057","title":"60 Degrees Pharmaceuticals, Inc.盘中异动 大幅跳水5.38%报1.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382057","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514382057?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:55","pubTimestamp":1740671735,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时55分,60 Degrees Pharmaceuticals, Inc.股票出现异动,股价急速跳水5.38%。60 Degrees Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.73%。60 Degrees Pharmaceuticals, Inc.公司简介:60 Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227235535abdf838a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227235535abdf838a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514562508","title":"60 Degrees Pharmaceuticals, Inc.盘中异动 大幅拉升6.77%报2.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514562508","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514562508?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:31","pubTimestamp":1740580269,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时31分,60 Degrees Pharmaceuticals, Inc.股票出现波动,股价大幅上涨6.77%。60 Degrees Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为0.12%。60 Degrees Pharmaceuticals, Inc.公司简介:60 Degrees Pharmaceuticals Inc作为一家专业制药公司运营,目标是利用生物科学和应用研究来开发和商业化预防和治疗传染病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022622311096314f04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022622311096314f04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.60degreespharma.com","stockEarnings":[{"period":"1week","weight":-0.1611},{"period":"1month","weight":-0.2898},{"period":"3month","weight":-0.247},{"period":"6month","weight":-0.6988},{"period":"1year","weight":-0.7736},{"period":"ytd","weight":-0.3852}],"compareEarnings":[{"period":"1week","weight":0.0048},{"period":"1month","weight":-0.0068},{"period":"3month","weight":0.0292},{"period":"6month","weight":0.0719},{"period":"1year","weight":0.169},{"period":"ytd","weight":0.0876}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"60 Degrees Pharmaceuticals, Inc.于2022年6月1日在特拉华州注册成立,此前与一家同名的有限责任公司合并。该公司是一家专业制药公司,专注于开发和商业化治疗传染病的疗法。其产品Arakoda(一种疟疾预防药物)自2019年起上市,其研发管线还包括其他虫媒、真菌和病毒性疾病项目。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040319},{"month":2,"riseRate":0,"avgChangeRate":-0.262735},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.15171},{"month":4,"riseRate":0.333333,"avgChangeRate":0.079946},{"month":5,"riseRate":0.333333,"avgChangeRate":0.058798},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.011364},{"month":7,"riseRate":0,"avgChangeRate":-0.380379},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.188581},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.16297},{"month":10,"riseRate":0,"avgChangeRate":-0.229986},{"month":11,"riseRate":0.666667,"avgChangeRate":0.078807},{"month":12,"riseRate":0.666667,"avgChangeRate":0.11386}],"exchange":"NASDAQ","name":"60 degrees pharmaceuticals, Inc.","nameEN":"60 degrees pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"60 degrees pharmaceuticals, Inc.(SXTP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供60 degrees pharmaceuticals, Inc.(SXTP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"60 degrees pharmaceuticals, Inc.,SXTP,60 degrees pharmaceuticals, Inc.股票,60 degrees pharmaceuticals, Inc.股票老虎,60 degrees pharmaceuticals, Inc.股票老虎国际,60 degrees pharmaceuticals, Inc.行情,60 degrees pharmaceuticals, Inc.股票行情,60 degrees pharmaceuticals, Inc.股价,60 degrees pharmaceuticals, Inc.股市,60 degrees pharmaceuticals, Inc.股票价格,60 degrees pharmaceuticals, Inc.股票交易,60 degrees pharmaceuticals, Inc.股票购买,60 degrees pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"60 degrees pharmaceuticals, Inc.(SXTP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供60 degrees pharmaceuticals, Inc.(SXTP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}